Literature DB >> 20357479

Characterization of the T-cell epitopes of the major peach allergen Pru p 3.

E A Pastorello1, M Monza, V Pravettoni, R Longhi, P Bonara, J Scibilia, L Primavesi, R Scorza.   

Abstract

BACKGROUND: Pru p 3 is the major peach allergen recognized by more than 90% of peach-allergic individuals of the Mediterranean area. Identification of the dominant Pru p 3 T-cell epitopes can improve our understanding of the immune responses against this protein and could be helpful in the development of hypoallergenic immunotherapy. For this purpose, we examined the phenotypes, specificities and cytokine secretion profiles of proliferating T cells in response to Pru p 3 in peach-allergic individuals.
METHODS: Peripheral blood mononuclear cells from 15 peach-allergic patients were incubated with Pru p 3. The proliferation of antigen-specific T-cell lines (TCLs) was assessed by tritiated methylthymidine incorporation. T-cell epitopes were identified by analyzing the reactivity of TCLs against 8 overlapping peptides spanning the entire length of Pru p 3. We characterized the phenotype of Pru-p-3-specific TCLs by flow cytometry and analyzed their production of interleukin (IL) 4 and gamma-interferon (IFN-gamma) by ELISA.
RESULTS: Ninety-two Pru-p-3-specific TCLs were isolated (stimulation index > or =5). These TCLs proliferated mainly in response to Pru p 3(12-27) and Pru p 3(57-72). Pru-p-3-specific TCLs were mainly CD4+ (81%) and expressed cell surface CD30. In addition, TCLs produced high levels of IL-4 and low levels of IFN-gamma, indicating a Th2 phenotype.
CONCLUSIONS: Two immunodominant T-cell-reactive regions of Pru p 3 were identified: Pru p 3(12-27) and Pru p 3(57-72). These peptides showed a differential ability to elicit a Th2 response. Taken together, our results provide a better understanding of the immunological T-cell reactivity against Pru p 3. Copyright (c) 2010 S. Karger AG, Basel.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20357479     DOI: 10.1159/000301573

Source DB:  PubMed          Journal:  Int Arch Allergy Immunol        ISSN: 1018-2438            Impact factor:   2.749


  4 in total

1.  Sensitization prevalence, antibody cross-reactivity and immunogenic peptide profile of Api g 2, the non-specific lipid transfer protein 1 of celery.

Authors:  Gabriele Gadermaier; Michael Hauser; Matthias Egger; Rosetta Ferrara; Peter Briza; Keity Souza Santos; Danila Zennaro; Tamara Girbl; Laurian Zuidmeer-Jongejan; Adriano Mari; Fatima Ferreira
Journal:  PLoS One       Date:  2011-08-29       Impact factor: 3.240

2.  FAST: towards safe and effective subcutaneous immunotherapy of persistent life-threatening food allergies.

Authors:  Laurian Zuidmeer-Jongejan; Montserrat Fernandez-Rivas; Lars K Poulsen; Angela Neubauer; Juan Asturias; Lars Blom; Joyce Boye; Carsten Bindslev-Jensen; Michael Clausen; Rosa Ferrara; Paula Garosi; Hans Huber; Bettina M Jensen; Stef Koppelman; Marek L Kowalski; Anna Lewandowska-Polak; Birgit Linhart; Bernard Maillere; Adriano Mari; Alberto Martinez; Clare En Mills; Claudio Nicoletti; Dirk-Jan Opstelten; Nikos G Papadopoulos; Antonio Portoles; Neil Rigby; Enrico Scala; Heidi J Schnoor; Sigurveig T Sigurdardottir; George Stavroulakis; Frank Stolz; Ines Swoboda; Rudolf Valenta; Rob van den Hout; Serge A Versteeg; Marianne Witten; Ronald van Ree
Journal:  Clin Transl Allergy       Date:  2012-03-09       Impact factor: 5.871

3.  Correlation of sensitizing capacity and T-cell recognition within the Bet v 1 family.

Authors:  Claudia Kitzmüller; Nora Zulehner; Anargyros Roulias; Peter Briza; Fatima Ferreira; Ingrid Faé; Gottfried F Fischer; Barbara Bohle
Journal:  J Allergy Clin Immunol       Date:  2015-02-07       Impact factor: 10.793

4.  Predicting HLA CD4 Immunogenicity in Human Populations.

Authors:  Sandeep Kumar Dhanda; Edita Karosiene; Lindy Edwards; Alba Grifoni; Sinu Paul; Massimo Andreatta; Daniela Weiskopf; John Sidney; Morten Nielsen; Bjoern Peters; Alessandro Sette
Journal:  Front Immunol       Date:  2018-06-14       Impact factor: 7.561

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.